Immutep Limited (IMMP)
Nasdaq · Healthcare · Biotechnology
$4.27−1.84%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $31.5M
- 52-week range
- $4.17 – $70.60
- 52-week change
- −88.85%
- EPS (trailing)
- −$7.30
About Immutep Limited
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma.
Headquarters: Sydney, Australia · immutep.com